Lupin gets USFDA nod for amifampridine tablets, eligible for 180-day generic exclusivity

What happened

Lupin received USFDA approval for its 10 mg amifampridine tablets, which are bioequivalent to Firdapse. The company is eligible for 180 days of shared generic exclusivity as one of the first applicants to file, and the tablets are approved for the indication in their approved labelling.

Confirmed

Global impact / market context

Approval allows Lupin to sell a generic version for the approved use, while shared exclusivity may limit competition from other generic applicants during the stated period. If sales follow, the medicine could add revenue; the article gives no sales forecast for this product.

Analyst inference

The article also reports a separate recent USFDA approval for Lupin’s phytonadione injection, whose estimated US sales were $52.3 million annually. Lupin shares ended down 0.62% on the BSE, but the article does not link that move to either approval.

Confirmed

What to watch

1. Watch for Lupin’s launch timing and any disclosed sales contribution from amifampridine; the article confirms approval and eligibility but gives no launch date or revenue estimate. Analyst inference
2. Check whether the 180-day shared exclusivity period begins and how many other first applicants share it, since those details could shape early generic competition. Analyst inference
3. Track whether Lupin reports further US regulatory approvals or commercial progress for its recently approved phytonadione injection, whose estimated annual US sales were $52.3 million. Analyst inference

Evidence

• Original source link unavailable